Form 4: Immunome CEO Acquires 150,000 Shares in Public Offering

Immunome's CEO, Clay B. Siegall, purchased 150,000 shares of common stock at $7.75 per share as part of a recent public offering.

Summary

• Immunome's CEO, Clay B. Siegall, has acquired 150,000 shares of the company's common stock.
• The shares were purchased at a price of $7.75 each.
• This transaction occurred on January 31, 2025.
• The purchase was made in connection with Immunome's recently completed underwritten public offering.
• Following this transaction, Mr. Siegall directly owns 669,636 shares of Immunome stock.

Sentiment

Score: 7

Explanation: The CEO's purchase of shares is a positive signal, indicating confidence in the company's future, but it's a standard action after a public offering.

Positives

• The CEO's purchase of shares demonstrates confidence in the company's future.
• The purchase was part of a successful public offering, indicating market interest in Immunome.

Industry Context

This type of transaction is common after a public offering, where insiders may purchase shares to show confidence in the company's prospects.

Comparison to Industry Standards

• Insider purchases are a common occurrence after public offerings across the biotech industry.
• The size of the purchase, 150,000 shares, is significant and indicates a strong belief in the company's future performance.
• Comparable companies often see similar insider activity following capital raises, with executives purchasing shares to align their interests with shareholders.

Stakeholder Impact

• The CEO's purchase may positively influence shareholder confidence.
• The purchase aligns management's interests with those of shareholders.

Key Dates

Keywords

Immunome, IMNM, Clay B. Siegall, Public Offering, Share Purchase, CEO, Common Stock, Insider Transaction